ReviewKidney research and clinical practice2016
Metabolic syndrome and obesity in peritoneal dialysis.
Review in Kidney research and clinical practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of metabolic syndrome in patients with end-stage renal disease: a systematic review and meta-analysis.International urology and nephrology · 2024Pooled it
- Management of Hypertension in Patients Undergoing Peritoneal Dialysis: A Narrative Review.Cureus · 2026Review
- Lesson for the clinical nephrologist: glucagon-like peptide-1 receptor agonists (GLP-1 RA) in a patient with obesity and diabetic kidney disease on peritoneal dialysis.Journal of nephrology · 2025Article
- Association of the remnant cholesterol to high-density lipoprotein cholesterol ratio with mortality in peritoneal dialysis patients.Lipids in health and disease · 2025Article
- The effect of body mass index on mortality, peritonitis, technique proficiency and residual renal function in peritoneal dialysis patients.International urology and nephrology · 2024Article
- Adipose and serum zinc alpha-2-glycoprotein (ZAG) expressions predict longitudinal change of adiposity, wasting and predict survival in dialysis patients.Scientific reports · 2022Article
- Association analysis of body composition with survival among prevalent peritoneal dialysis patients.International urology and nephrology · 2022Article
- Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis.Trends in endocrinology and metabolism: TEM · 2021Review
- How to Improve the Biocompatibility of Peritoneal Dialysis Solutions (without Jeopardizing the Patient's Health).International journal of molecular sciences · 2021Review
- Abdominal Distention in a Patient on Peritoneal Dialysis.Kidney360 · 2020Article
- Clinical value of body composition monitor to evaluate lean and fat tissue mass in peritoneal dialysis.European journal of clinical nutrition · 2019Observational
- Clinical characterization and prognostic implications of metabolic syndrome in patients undergoing peritoneal dialysis at a Chinese center.The Journal of international medical research · 2019Article
- Impact of body mass index on survival in patients undergoing peritoneal dialysis: Analysis of data from the Insan Memorial End-Stage Renal Disease Registry of Korea (1985-2014).Kidney research and clinical practice · 2019Article
- Risk, Severity, and Predictors of Obstructive Sleep Apnea in Hemodialysis and Peritoneal Dialysis Patients.International journal of environmental research and public health · 2018Article
- Fasting serum resistin level positively correlates with metabolic syndrome in patients on peritoneal dialysis.International journal of clinical and experimental pathology · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MS) refers to clustering of features related to increased risk of cardiovascular disease, which include obesity or central obesity, dyslipidemia, diabetes mellitus or insulin resistance, together with hypertension. The prevalence of MS in end-stage renal failure patients on peritoneal dialysis is quite common, ranging from 40% to 60%, depending on the population studied and the definition used. However, there are controversies about the clinical outcome of patients with MS, particularly in the area of obesity. Whether peritoneal dialysis predisposes patients to MS is another unsolved issue. Despite these controversies, preventing patients from developing MS is important, at least from a theoretical point of view.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.